<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11680285</article-id><article-id pub-id-type="doi">10.3390/vaccines12121304</article-id><article-id pub-id-type="publisher-id">vaccines-12-01304</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Live Attenuated aTJ Vaccine Effectively Protects Pigeons Against Homologous PPMV-1 Challenge</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0003-2356-0481</contrib-id><name><surname>Zhang</surname><given-names>Shan</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing &#x02013; original draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing &#x02013; review &#x00026; editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af1-vaccines-12-01304" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Dahu</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><xref rid="af1-vaccines-12-01304" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Baojing</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><xref rid="af2-vaccines-12-01304" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Liang</surname><given-names>Ruinying</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af1-vaccines-12-01304" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Liang</surname><given-names>Lin</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af1-vaccines-12-01304" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0127-1235</contrib-id><name><surname>Tang</surname><given-names>Xinming</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing &#x02013; review &#x00026; editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-vaccines-12-01304" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Hou</surname><given-names>Shaohua</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><xref rid="af1-vaccines-12-01304" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Ding</surname><given-names>Chan</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af3-vaccines-12-01304" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Qiu</surname><given-names>Xusheng</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing &#x02013; review &#x00026; editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding acquisition/">Funding acquisition</role><xref rid="af3-vaccines-12-01304" ref-type="aff">3</xref><xref rid="c1-vaccines-12-01304" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Ding</surname><given-names>Jiabo</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding acquisition/">Funding acquisition</role><xref rid="af1-vaccines-12-01304" ref-type="aff">1</xref><xref rid="c1-vaccines-12-01304" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Feng</surname><given-names>Xiuli</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-12-01304"><label>1</label>Institute of Animal Sciences, Chinese Academy of Agricultural Sciences, Beijing 100193, China; <email>zhangshan0276@163.com</email> (S.Z.); <email>liudahu961196@163.com</email> (D.L.); <email>liangruiying@caas.cn</email> (R.L.); <email>lianglin@caas.cn</email> (L.L.); <email>tangxinming@caas.cn</email> (X.T.); <email>houshaohua@caas.cn</email> (S.H.)</aff><aff id="af2-vaccines-12-01304"><label>2</label>Beijing Xinhexiang Technology Co., LLC, Beijing 100085, China; <email>lbjxhxbio@163.com</email></aff><aff id="af3-vaccines-12-01304"><label>3</label>Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai 200241, China; <email>shoveldeen@shvri.ac.cn</email></aff><author-notes><corresp id="c1-vaccines-12-01304"><label>*</label>Correspondence: <email>xsqiu1981@shvri.ac.cn</email> (X.Q.); <email>dingjiabo@caas.cn</email> (J.D.)</corresp></author-notes><pub-date pub-type="epub"><day>22</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>12</volume><issue>12</issue><elocation-id>1304</elocation-id><history><date date-type="received"><day>30</day><month>10</month><year>2024</year></date><date date-type="rev-recd"><day>18</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>19</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Background:</bold> Pigeon paramyxovirus type 1 (PPMV-1) is a significant pathogen affecting pigeon populations globally. The commonly used La Sota vaccine provides limited protection due to antigenic divergence from circulating PPMV-1 strains. An antigenically matched vaccine is needed to address this challenge. <bold>Methods:</bold> An attenuated aTJ strain was developed through reverse genetics by modifying the F protein cleavage site of the virulent TJ-WT strain. Pigeons were immunized twice with the aTJ strain via eyedrop and intranasal routes, followed by a challenge with a virulent PPMV-1 strain ten days after the booster immunization. <bold>Results:</bold> The attenuated aTJ strain induced robust serum antibody titers post-booster immunization, and vaccinated pigeons showed strong protection upon challenge, with significantly reduced morbidity, mortality, and viral shedding compared to controls. <bold>Conclusions:</bold> These findings suggest that the aTJ strain is a promising candidate for the promotion of PPMV-1 prevention and control, emphasizing the importance of antigenic matching in optimizing vaccine efficacy. </p></abstract><kwd-group><kwd>PPMV-1</kwd><kwd>reverse genetics</kwd><kwd>aTJ strain</kwd><kwd>booster immunization</kwd><kwd>vaccine efficacy</kwd></kwd-group><funding-group><award-group><funding-source>Agricultural Science and Technology Innovation Program of Chinese Academy of Agricultural Sciences</funding-source><award-id>ASTIP-IAS15</award-id></award-group><award-group><funding-source>Shanghai Agriculture Applied Technology Development Program, China</funding-source><award-id>202412</award-id></award-group><funding-statement>This research was funded by the Shanghai Agriculture Applied Technology Development Program, China (Grant No. 202412), and the Agricultural Science and Technology Innovation Program of Chinese Academy of Agricultural Sciences (grant no. ASTIP-IAS15).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-12-01304"><title>1. Introduction</title><p>Newcastle disease (ND), caused by Newcastle Disease Virus (NDV), is a highly contagious disease that affects a wide range of avian species and leads to considerable economic losses in the global poultry industry [<xref rid="B1-vaccines-12-01304" ref-type="bibr">1</xref>]. NDV, also known as Avian Paramyxovirus Type 1 (APMV-1), is classified under the genus <italic toggle="yes">Orthoavulavirus</italic> in the family <italic toggle="yes">Paramyxoviridae</italic> [<xref rid="B2-vaccines-12-01304" ref-type="bibr">2</xref>]. Its non-segmented, negative-sense RNA genome is approximately 15.2 kb in length and encodes six major structural proteins: nucleoprotein (NP), phosphoprotein (P), matrix protein (M), fusion protein (F), hemagglutinin-neuraminidase (HN), and large polymerase (L). This genome follows the &#x0201c;rule of six&#x0201d; for genome length, a key feature in the replication process of paramyxoviruses [<xref rid="B3-vaccines-12-01304" ref-type="bibr">3</xref>]. Pigeon Newcastle Disease Virus, also named Pigeon Paramyxovirus-1 (PPMV-1), is a host-specific variant of NDV and predominantly falls within genotype VI of Class II. The PPMV-1 genome is approximately 15,192 nucleotides in length. First identified in Middle Eastern pigeons in 1978 [<xref rid="B4-vaccines-12-01304" ref-type="bibr">4</xref>], PPMV-1 contributed to the third ND panzootic in the 1980s [<xref rid="B5-vaccines-12-01304" ref-type="bibr">5</xref>]. Pigeons of all ages are susceptible to this virus, with the morbidity and mortality rates exceeding 50% [<xref rid="B6-vaccines-12-01304" ref-type="bibr">6</xref>]. Common clinical signs in infected pigeons include neurological symptoms such as paralysis, torticollis, and twisted neck, with the neurotropic, acute form being the most prevalent [<xref rid="B7-vaccines-12-01304" ref-type="bibr">7</xref>,<xref rid="B8-vaccines-12-01304" ref-type="bibr">8</xref>]. The disease was first reported in China in 1985, and it continues to pose a significant threat to both the pigeon breeding industry and wild bird populations [<xref rid="B4-vaccines-12-01304" ref-type="bibr">4</xref>].</p><p>Although commercial vaccination programs have been employed to control ND in poultry, current vaccines like the La Sota strain (genotype II), have demonstrated limited efficacy in pigeons [<xref rid="B9-vaccines-12-01304" ref-type="bibr">9</xref>,<xref rid="B10-vaccines-12-01304" ref-type="bibr">10</xref>]. Pigeons often display high viral shedding and morbidity due to inadequate immune protection, primarily caused by substantial antigenic differences between pigeon NDV strains (Class II, genotype VI) and the chicken-derived vaccine strains [<xref rid="B11-vaccines-12-01304" ref-type="bibr">11</xref>]. Pigeon farming, including both meat production and racing pigeon breeding, has grown rapidly due to its low costs and high economic value. In China, approximately 40 million pairs of breeding pigeons exist, with around 700 million pigeons sold for meat annually [<xref rid="B12-vaccines-12-01304" ref-type="bibr">12</xref>]. Additionally, the global racing pigeon industry is thriving, with competitions and high-value auctions driving economic growth [<xref rid="B13-vaccines-12-01304" ref-type="bibr">13</xref>,<xref rid="B14-vaccines-12-01304" ref-type="bibr">14</xref>]. As pigeon farming becomes more large-scale and intensive, the frequent introduction of breeding pigeons and increased interregional movement heightens the risk of disease transmission, posing significant challenges to disease control [<xref rid="B12-vaccines-12-01304" ref-type="bibr">12</xref>,<xref rid="B15-vaccines-12-01304" ref-type="bibr">15</xref>]. While the pathogenicity of PPMV-1 varies among different host species, several studies have shown that its virulence increases with subsequent passages through chickens [<xref rid="B16-vaccines-12-01304" ref-type="bibr">16</xref>,<xref rid="B17-vaccines-12-01304" ref-type="bibr">17</xref>]. The extensive flight range of pigeons facilitates the broader spread of PPMV-1, with prolonged viral shedding contaminating the environment and raising the risk of cross-species transmission [<xref rid="B14-vaccines-12-01304" ref-type="bibr">14</xref>]. Notably, PPMV-1 has been linked to fatal respiratory diseases in immunocompromised human patients, raising significant public health concerns [<xref rid="B18-vaccines-12-01304" ref-type="bibr">18</xref>]. These factors highlight the urgent need for pigeon-specific ND vaccines tailored to genotype VI&#x02019;s unique antigenic properties, which could significantly improve pigeon immune protection and ensure the healthy development of the pigeon farming industry. Numerous studies have substantiated that vaccines genotypically aligned with epidemic strains markedly enhance ND control by diminishing viral shedding among affected birds [<xref rid="B19-vaccines-12-01304" ref-type="bibr">19</xref>,<xref rid="B20-vaccines-12-01304" ref-type="bibr">20</xref>,<xref rid="B21-vaccines-12-01304" ref-type="bibr">21</xref>]. While using inactivated epidemic strains as vaccines offers a strategic approach [<xref rid="B13-vaccines-12-01304" ref-type="bibr">13</xref>,<xref rid="B22-vaccines-12-01304" ref-type="bibr">22</xref>], developing these vaccines from virulent NDV strains requires strict operational and laboratory protocols. On the other hand, live attenuated NDV vaccines are well suited for mass production and are commonly used for routine large-scale vaccination through spray or drinking water administration [<xref rid="B23-vaccines-12-01304" ref-type="bibr">23</xref>]. Understanding the pathogenicity of NDV is crucial for vaccine development, as it is closely associated with the amino acid sequence of the F protein cleavage site (Fcs). Virulent viruses typically possess a polybasic amino acid motif of <sub>112</sub>R/KRQK/RRF<sub>117</sub>, whereas lentogenic viruses feature a monobasic amino acid sequence of <sub>112</sub>G/EK/RQG/ER-L<sub>117</sub> [<xref rid="B24-vaccines-12-01304" ref-type="bibr">24</xref>,<xref rid="B25-vaccines-12-01304" ref-type="bibr">25</xref>,<xref rid="B26-vaccines-12-01304" ref-type="bibr">26</xref>]. The Fcs of PPMV-1 is commonly <sub>112</sub>RRQKRF<sub>117</sub>, which is characteristic of virulent strains [<xref rid="B27-vaccines-12-01304" ref-type="bibr">27</xref>]. Research using reverse genetics has demonstrated that replacing the Fcs of the La Sota strain with that of a virulent NDV strain results in increased virulence [<xref rid="B28-vaccines-12-01304" ref-type="bibr">28</xref>]. Conversely, modifying the Fcs of a highly virulent NDV to match the La Sota strain significantly reduces its virulence while preserving immunogenicity, making the recombinant virus a strong candidate for vaccine development [<xref rid="B20-vaccines-12-01304" ref-type="bibr">20</xref>,<xref rid="B29-vaccines-12-01304" ref-type="bibr">29</xref>]. These findings have laid the foundation for the use of attenuated viruses in ND vaccine development [<xref rid="B20-vaccines-12-01304" ref-type="bibr">20</xref>].</p><p>In this study, we employed a reverse genetics platform to generate an attenuated pigeon NDV strain by introducing mutations at the Fcs to match the La Sota sequence. Immunization of pigeons with the rescued strain, followed by booster immunization, resulted in robust serum antibody titers and significant protection against PPMV-1, including reduced morbidity, mortality, and viral shedding. These findings demonstrate that the attenuated strain not only holds promise as an effective vaccine candidate for controlling ND in pigeons but also offers a feasible approach to enhance biosecurity and reduce the risk of cross-species transmission.</p></sec><sec id="sec2-vaccines-12-01304"><title>2. Materials and Methods</title><sec id="sec2dot1-vaccines-12-01304"><title>2.1. Ethics Statement</title><p>The protocol involving animals was approved by the Animal Welfare and Ethics Committee of the Institute of Animal Sciences (IAS), Chinese Academy of Agricultural Sciences (Approval No. ISA2023-120, CAAS, Beijing, China).</p></sec><sec id="sec2dot2-vaccines-12-01304"><title>2.2. Virus, Cells, and Plasmids</title><p>Pigeon paramyxovirus-1 Pigeon/TJ/CH/020/2020(TJ-WT) strain, GenBank PQ563353, was isolated from pigeons in China by our laboratory and identified as the dominant epidemic strain of subtype VI.2.1.1.2.2 [<xref rid="B30-vaccines-12-01304" ref-type="bibr">30</xref>]. TJ-WT was propagated in 9-day-old specific pathogen-free (SPF) chicken embryos (Beijing Boehringer Ingelheim Vital Bio, Beijing, China). Baby hamster kidney fibroblast cells (BHK21) were from the Cell Resource Center, Peking Union Medical College. BSR-T7/5 cells were kindly provided by Zhigao Bu and maintained in our laboratory for further experiments. The pLaSota-DM were kept in our laboratory [<xref rid="B31-vaccines-12-01304" ref-type="bibr">31</xref>]. pCI-neo plasmid was purchased from Miao Ling biotechnology (Shanghai, China).</p></sec><sec id="sec2dot3-vaccines-12-01304"><title>2.3. Construction of Infectious cDNA Clones</title><p>Viral RNA was extracted from the allantoic fluid infected with the TJ-WT strain by the FastPure Viral DNA/RNA Mini Kit (Vazyme Biotech, Nanjing, China). First-strand complementary DNA (cDNA) was synthesized using the Hifair III 1st Strand cDNA Synthesis Kit (YEASEN, Shanghai, China). To obtain the full genome sequence of the TJ-WT strain, cDNA was used as a template for PCR amplification with 11 pairs of primers [<xref rid="B32-vaccines-12-01304" ref-type="bibr">32</xref>]. The amplification was performed using PrimeSTAR MAX DNA Polymerase (Takara, Kyoto, Japan), according to the manufacturer&#x02019;s instructions. All PCR products were sequenced by the Sanger method and assembled using the SeqMan program (Lasergene software v7.1, DNAstar, Inc., Madison, WI, USA). To construct the infectious clone, the pTVT vector was derived from pLaSota-DM plasmid using TVT-F and TVT-R primers. The TJ-WT genome was inserted between the T7 promoter and the Hepatitis Delta Virus ribozyme sequence, which were retained from the pLaSota-DM plasmid. This configuration facilitates viral RNA production in cells that express T7 RNA polymerase. The genome was divided into five segments (C1, S2, S3, C4, and C5) for amplification and ligation into the pTVT vector (<xref rid="vaccines-12-01304-t001" ref-type="table">Table 1</xref>). A nonsense mutation at the KpnI site in the M gene was introduced using S1-R and S2-F primers to facilitate detection, and the Fcs was replaced with that of La Sota using S2-R and S3-F primers. As shown in <xref rid="vaccines-12-01304-f001" ref-type="fig">Figure 1</xref>, homologous recombination was employed to link C1 and S2 to the pTVT vector by the Seamless Cloning and Assembly Kit (TransGen, Beijing, China). After obtaining the positive plasmid, digestion with MluI (NEB, Ipswich, MA, USA) was performed, followed by insertion of the S3 fragment. This process was repeated for the C4 and C5 fragments, resulting in the full-length infectious clone of the attenuated TJ-WT strain, named TVT-aTJ.</p></sec><sec id="sec2dot4-vaccines-12-01304"><title>2.4. Construction of the Helper Plasmids</title><p>Based on the nucleotide sequence of the TJ-WT strain, homologous recombination primers were designed to insert the NP, P, and L protein ORF regions into the multiple cloning site of the pCI-neo mammalian expression vector. To enhance gene expression, a Kozak sequence (GCCACC) was introduced upstream of the start codon (<xref rid="vaccines-12-01304-t001" ref-type="table">Table 1</xref>). The L ORF was divided into two segments, L1 and L2, to ensure accurate amplification. The amplification products were then ligated into the pCI-neo vector, which has been amplified using the pCI-VF/R primers. Correct clones were confirmed by sequencing, and the resulting plasmids were designated pCI-6NP, pCI-6P, and pCI-6L.</p></sec><sec id="sec2dot5-vaccines-12-01304"><title>2.5. Rescue and Pathogenicity of Viruses</title><p>The full-length plasmid TVT-aTJ, along with the helper plasmids pCI-6NP, pCI-6P, and pCI-6L, were co-transfected into BSR-T7 cells using Lipofectamine 2000 (Thermo Fisher, Waltham, MA, USA) in a 4:2:2:1 ratio to rescue the virus. After 4 h, the medium was replaced with Dulbecco&#x02019;s modified Eagle&#x02019;s medium (DMEM) supplemented with 2% fetal bovine serum (FBS, Gibco, Waltham, MA, USA) and 1 &#x000b5;g/mL Tosyl phenylalanyl chloromethyl ketone (TPCK)-trypsin. Cells and supernatants were subsequently injected into 9-day-old SPF chicken embryos. The presence of the rescued virus was confirmed by hemagglutination (HA) testing according to the World Organisation for Animal Health (WOAH) manual [<xref rid="B33-vaccines-12-01304" ref-type="bibr">33</xref>]. Additionally, PPMV1-3 primers were used to detect the genetic marker, with the PCR product digested by KpnI to verify its presence. PPMV1&#x02013;4 primers were employed to sequence the Fcs to confirm the introduced mutations [<xref rid="B32-vaccines-12-01304" ref-type="bibr">32</xref>]. The pathogenicity of the rescued virus was assessed by the standard mean death time (MDT) and intracerebral pathogenicity index (ICPI) tests, as previously described [<xref rid="B33-vaccines-12-01304" ref-type="bibr">33</xref>].</p></sec><sec id="sec2dot6-vaccines-12-01304"><title>2.6. Virus Titration and Growth Curve</title><p>Viral titers were determined using the 50% embryo infectious dose (EID<sub>50</sub>) method in 9-day-old chicken embryos [<xref rid="B33-vaccines-12-01304" ref-type="bibr">33</xref>] employing the fifth-generation virus isolated from chicken embryo allantoic fluid. Additionally, viral growth kinetics were evaluated using the 50% tissue culture infectious dose (TCID<sub>50</sub>) assay in BHK21 cells. Briefly, 100 &#x003bc;L of ten-fold serial dilutions of the virus were added to a 96-well plate containing a monolayer of BHK21 cells, with each dilution replicated six times. After 1 h of incubation, the supernatant was replaced with 100 &#x000b5;L of fresh DMEM containing 2% FBS and 1 &#x000b5;g/mL TPCK-trypsin. The cells were incubated for 60 h, and cytopathic effects (CPE) were observed to assess viral infection. TCID<sub>50</sub> values were calculated using the Reed&#x02013;Muench method [<xref rid="B34-vaccines-12-01304" ref-type="bibr">34</xref>]. Based on the calculated virus titers, BHK21 cell monolayers were infected with virus at a multiplicity of infection (MOI) of 1. Supernatants were collected every 12 h for further TCID<sub>50</sub> determination.</p></sec><sec id="sec2dot7-vaccines-12-01304"><title>2.7. Immunization and Challenge</title><p>Four-month-old pigeons, with no prior exposure to NDV or vaccination, were sourced from a farm in Beijing, China. The pigeons were randomly divided into two groups (<italic toggle="yes">n</italic> = 10 per group). One group was immunized with the aTJ strain (10<sup>6</sup> EID<sub>50</sub>) via eyedrop and intranasal routes, while the other group was administered PBS. Both groups were housed separately in negative pressure isolators to prevent cross-contamination between groups. Twenty-one days post-primary immunization (dpi), a booster dose was administered using the same method and dosage. Blood samples were collected on 7, 14, 21, 28, and 31 dpi for hemagglutination inhibition (HI) assays to assess the NDV antibody levels. On 31 dpi, pigeons were challenged with variant NDV genotype VI (TJ-WT) at a dose of 10<sup>6</sup> EID<sub>50</sub> via intramuscular injection. Clinical signs and mortality were monitored daily for 14 days post-challenge (dpc) [<xref rid="B35-vaccines-12-01304" ref-type="bibr">35</xref>,<xref rid="B36-vaccines-12-01304" ref-type="bibr">36</xref>]. Cloacal swabs were collected on 5 and 10 dpc for virus isolation. At the end of the experiment, all pigeons were euthanized with carbon dioxide.</p></sec><sec id="sec2dot8-vaccines-12-01304"><title>2.8. HI Assay</title><p>Serum samples were collected weekly from each group. To eliminate nonspecific agglutination, sera were incubated with 20% chicken red blood cells (RBCs) at 4 &#x000b0;C for 1 h, followed by centrifugation at 800&#x000d7; <italic toggle="yes">g</italic> for five minutes. The supernatants were collected and saved at &#x02212;80 &#x000b0;C. HI antibody titers against NDV were determined using standard procedures [<xref rid="B33-vaccines-12-01304" ref-type="bibr">33</xref>]. Both aTJ and La Sota strains were used as 4 HA unit antigens to measure the HI titers, enabling a comparison of the immune responses elicited by the two strains.</p></sec><sec id="sec2dot9-vaccines-12-01304"><title>2.9. Virus Isolation</title><p>Cloacal swabs were collected from each pigeon in each group at 5 and 10 dpc to evaluate viral shedding. Swabs were immersed in 1 mL of phosphate-buffered saline (PBS) containing penicillin (10,000 units/mL), streptomycin (10 mg/mL), and gentamicin (250 &#x000b5;g/mL) and incubated at 37 &#x000b0;C for 2 h. Subsequently, 200 &#x003bc;L supernatant was inoculated into 9-day-old chicken embryos. The virus presence was confirmed 4 days later via the HA assay.</p></sec><sec id="sec2dot10-vaccines-12-01304"><title>2.10. Statistical Analysis</title><p>All statistical analyses were conducted using GraphPad Prism Software 9.5. HI titers were presented as the median and interquartile range (IQR) and were analyzed using the nonparametric Mann&#x02013;Whitney <italic toggle="yes">U</italic> test. Morbidity and mortality rates between groups were compared using the chi-square test and Fisher&#x02019;s exact test. Statistical significance was defined as <italic toggle="yes">p</italic> &#x0003c; 0.05, with levels of significance indicated as * <italic toggle="yes">p</italic> &#x0003c; 0.05, ** <italic toggle="yes">p</italic> &#x0003c; 0.01, *** <italic toggle="yes">p</italic> &#x0003c; 0.001, and **** <italic toggle="yes">p</italic> &#x0003c; 0.0001.</p></sec></sec><sec sec-type="results" id="sec3-vaccines-12-01304"><title>3. Results</title><sec id="sec3dot1-vaccines-12-01304"><title>3.1. Generation of Recombinant aTJ Virus</title><p>The complete genome of strain TJ-WT was amplified using eleven primer pairs, generating overlapping fragments that were subsequently assembled to produce the full genome sequence (<xref rid="app1-vaccines-12-01304" ref-type="app">Figure S1</xref>). The assembled genome was determined to be 15,192 nucleotides, consistent with other NDV genotype VI strains. The Fcs was identified as <sub>112</sub>RRQKRF<sub>117</sub>, indicating a virulent phenotype. A full-length infectious clone of the attenuated aTJ strain was constructed by assembling five overlapping cDNA fragments (<xref rid="app1-vaccines-12-01304" ref-type="app">Figure S2</xref>) replicating the TJ-WT genome, except for a silent mutation introduced at the KpnI site in the M gene for detection purposes (<xref rid="vaccines-12-01304-f001" ref-type="fig">Figure 1</xref>). The genetic marker was verified by KpnI digestion of the PCR product amplified with PPMV1-3 primers. To attenuate the virus, the wild-type Fcs was replaced with the avirulent <sub>112</sub>GRQGRL<sub>117</sub>, commonly found in La Sota strains. This substitution resulted in three amino acid changes (positions 112, 115, and 117), confirmed through sequencing (<xref rid="vaccines-12-01304-f002" ref-type="fig">Figure 2</xref>B). The recombinant aTJ virus was successfully rescued by co-transfecting BSR T7/5 cells with the full-length plasmid (TVT-aTJ) and helper plasmids encoding NP, P, and L proteins. After 48 h, the cells and supernatants were inoculated into 9-day-old embryonated chicken eggs, and the presence of the rescued virus was confirmed by HA testing, which showed an initial HA titer of 3 log2.</p></sec><sec id="sec3dot2-vaccines-12-01304"><title>3.2. Biological Characterization of aTJ</title><p>The virulence and replication characteristics of the fifth-generation aTJ virus, propagated in chicken embryo allantoic fluid, was assessed to confirm the attenuation and replication properties. Compared to the parental TJ-WT strain, aTJ exhibited significant attenuation, with the ICPI reduced to 0.2 and a MDT of 146 h (<xref rid="vaccines-12-01304-t002" ref-type="table">Table 2</xref>), indicating its classification as a lentogenic strain. The viral growth kinetics were assessed in BHK21 cells at a MOI of 1 (<xref rid="vaccines-12-01304-f003" ref-type="fig">Figure 3</xref>). Both the aTJ and TJ-WT strains reached peak titers at 48 h post-infection, with aTJ displaying slightly lower overall titers compared to TJ-WT. These results confirm that aTJ retains efficient replication similar to the parental strain.</p><table-wrap position="anchor" id="vaccines-12-01304-t002"><object-id pub-id-type="pii">vaccines-12-01304-t002_Table 2</object-id><label>Table 2</label><caption><p>Virulence analysis results.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Strains</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">lgTCID<sub>50</sub>
<sup>1</sup> (0.1 mL)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">lgEID<sub>50</sub>
<sup>2</sup> (0.1 mL)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">MDT <sup>3</sup> (h)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">ICPI <sup>4</sup></th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">aTJ</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;8.63</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;9.00</td><td align="center" valign="middle" rowspan="1" colspan="1">146</td><td align="center" valign="middle" rowspan="1" colspan="1">0.20</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TJ-WT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;8.17</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;8.38</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">62</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.19</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> lgTCID<sub>50</sub>, logarithm base 10 of 50% tissue infectious dose.<sup>2</sup> lgEID<sub>50</sub>, logarithm base 10 of 50% egg culture infective dose.<sup>3</sup> MDT, mean death time.<sup>4</sup> ICPI, intracerebral pathogenicity index.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec3dot3-vaccines-12-01304"><title>3.3. Antibody Response</title><p>Serum samples were collected on 7, 14, 21, 28, and 31 dpi, and HI titers were measured using both the aTJ and La Sota strains as antigens (<xref rid="vaccines-12-01304-f004" ref-type="fig">Figure 4</xref>). Following the booster immunization on 21 dpi, the aTJ vaccine group exhibited a significant increase in antibody titers. In the HI assays using aTJ as the antigen (<xref rid="vaccines-12-01304-f004" ref-type="fig">Figure 4</xref>A), the aTJ group showed a sudden rise in antibody titers on 28 dpi, with the median titer slightly decreasing on 31 dpi, while the PBS control group remained negative throughout the experiment. The antibody titers in the aTJ group were significantly higher than those in the PBS group. Similarly, when La Sota was used as the antigen (<xref rid="vaccines-12-01304-f004" ref-type="fig">Figure 4</xref>B), some pigeons in the aTJ group were seroconverted by 28 dpi, though the median titer also declined slightly on 31 dpi. Notably, the antibody titers detected using aTJ as the antigen were higher than those observed with La Sota, indicating that the aTJ vaccine elicited a robust, strain-specific immune response.</p></sec><sec id="sec3dot4-vaccines-12-01304"><title>3.4. Clinical Signs in Vaccinated Pigeon After Challenge</title><p>Each group was challenged with the TJ-WT strain on day 10 post-boost immunization (31 dpi), with the clinical signs monitored daily for 14 days. Clinical symptoms observed in pigeons are shown in <xref rid="app1-vaccines-12-01304" ref-type="app">Figure S3</xref>, and detailed clinical observations for each group throughout the experiment are provided in <xref rid="app1-vaccines-12-01304" ref-type="app">Table S1</xref>. Clinical scores and survival curves are shown in <xref rid="vaccines-12-01304-f005" ref-type="fig">Figure 5</xref>. In the PBS group, clinical signs appeared at 4 dpc, including lethargy, ruffled feathers, and yellow-green or white, loose feces. Symptoms worsened, and one pigeon died on 6 dpc. From 9 dpc, mortality increased steadily, ultimately reaching 100% by 13 dpc, with a peak clinical score of 4.0. In contrast, in the aTJ group, only one pigeon exhibited mild clinical symptoms from 6 dpc, with a stable clinical score of 0.2, and no pigeons succumbed to the infection, resulting in a morbidity rate of 10% (1/10) and a mortality rate of 0% (0/10). These results demonstrate that the aTJ vaccine effectively protects pigeons from the lethal challenge of PPMV-1.</p></sec><sec id="sec3dot5-vaccines-12-01304"><title>3.5. Reduction in Virulent NDV Shedding</title><p>Virus shedding was evaluated through cloacal swabs collected at 5 and 10 dpc (<xref rid="vaccines-12-01304-t003" ref-type="table">Table 3</xref>). At 5 dpc, virus shedding was detected in 100% of the pigeons in the PBS control group while the aTJ group exhibited a shedding rate of 30% (3/10). By 10 dpc, virus shedding in the aTJ group decreased to 10% (1/10), while the PBS group maintained consistent shedding at 100%. Notably, the three pigeons in the aTJ group that tested positive for virus shedding at 5 dpc had HI antibody titers of less than 1 log2 at 31 dpi. Additionally, compared to the PBS group, the aTJ groups displayed significantly lower morbidity (10%, 1/10, <italic toggle="yes">p</italic> = 0.0001) and mortality rates (0%, 0/10, <italic toggle="yes">p</italic> &#x0003c; 0.0001). These results suggest that the live attenuated aTJ vaccine effectively reduces virus shedding while providing strong protection against morbidity and mortality.</p></sec></sec><sec sec-type="discussion" id="sec4-vaccines-12-01304"><title>4. Discussion</title><p>PPMV-1 was first detected in Hong Kong in 1985 and has since become a major pathogen impacting pigeon breeding in the region [<xref rid="B10-vaccines-12-01304" ref-type="bibr">10</xref>]. Inactivated and live attenuated La Sota strain vaccines are commonly used for PPMV-1 prevention. However, sporadic outbreaks of Newcastle disease continue, suggesting suboptimal vaccine protection and highlighting the need for improved strategies. PPMV-1 is an antigenically distinct genotype of NDV, classified as genotype VI. In recent years, the predominant circulating PPMV-1 strains have been subtypes VI.2.1.1.2.1 and VI.2.1.1.2.2, with VI.2.1.1.2.2 gradually emerging as the dominant strain [<xref rid="B37-vaccines-12-01304" ref-type="bibr">37</xref>,<xref rid="B38-vaccines-12-01304" ref-type="bibr">38</xref>]. The PPMV-1 strain TJ (WT) was isolated from a pigeon loft in Tianjin that had been vaccinated with the La Sota vaccine. This strain exhibited an antigenic similarity coefficient of 0.13 relative to La Sota, indicating significant antigenic divergence [<xref rid="B30-vaccines-12-01304" ref-type="bibr">30</xref>]. A lot of research has demonstrated that vaccines with a close antigenic relationship to the currently circulating strains may offer better protection compared to commercial vaccines [<xref rid="B20-vaccines-12-01304" ref-type="bibr">20</xref>,<xref rid="B39-vaccines-12-01304" ref-type="bibr">39</xref>,<xref rid="B40-vaccines-12-01304" ref-type="bibr">40</xref>]. Furthermore, live attenuated NDV vaccines are particularly well suited for mass production and are routinely utilized for large-scale vaccination via spray or drinking water administration, which significantly streamlines the vaccination process. Therefore, selecting an attenuated live vaccine that more closely matches the antigenicity of circulating strains may represent a more effective prevention strategy.</p><p>To address the challenges associated with PPMV-1, this study applied reverse genetic technology to develop an attenuated vaccine candidate. The virulent F protein cleavage site of the TJ-WT strain (<sub>112</sub>RRQKRF<sub>117</sub>) was replaced with the attenuated cleavage site (<sub>112</sub>GRQGRL<sub>117</sub>) typically present in the La Sota strain. This modification resulted in a significant reduction in virulence, as indicated by the ICPI of 0.2 and MDT of 146 h, consistent with an attenuated phenotype. The findings confirm that targeted mutations at the Fcs can effectively reduce virulence [<xref rid="B20-vaccines-12-01304" ref-type="bibr">20</xref>,<xref rid="B29-vaccines-12-01304" ref-type="bibr">29</xref>], thereby supporting the potential of aTJ as a viable vaccine candidate with diminished pathogenicity while retaining its immunogenic properties.</p><p>Further evaluation of the aTJ strain&#x02019;s protective efficacy as a live attenuated vaccine was conducted. The HI antibody titer, a key measure of humoral immunity, was undetectable in pigeons until 21 dpi, consistent with prior findings of delayed and weaker antibody responses to PPMV-1 compared to chickens [<xref rid="B41-vaccines-12-01304" ref-type="bibr">41</xref>]. Although no HI titers were detected until 21 dpi, this does not imply a lack of immune response. It is possible that cellular immunity, stimulated via eyedrop and intranasal routes, may have enhanced the humoral immune response upon booster immunization. Studies have shown that PPMV-1-infected pigeons exhibit elevated IFN-&#x003b3; levels, indicating a cell-mediated immune response [<xref rid="B42-vaccines-12-01304" ref-type="bibr">42</xref>,<xref rid="B43-vaccines-12-01304" ref-type="bibr">43</xref>,<xref rid="B44-vaccines-12-01304" ref-type="bibr">44</xref>,<xref rid="B45-vaccines-12-01304" ref-type="bibr">45</xref>,<xref rid="B46-vaccines-12-01304" ref-type="bibr">46</xref>]. This cellular immunity may have primed the pigeons for a stronger antibody response after the second immunization. Seroconversion (HI antibody titer) was observed on day 7 after the booster immunization, further confirming that the attenuated vaccine is capable of replicating in pigeons and eliciting a host immune response [<xref rid="B47-vaccines-12-01304" ref-type="bibr">47</xref>]. However, the antibody levels following the second immunization varied among individuals, with some pigeons rapidly producing antibody titers as high as 6 log2, while one pigeon remained at 0 log2. This variability is likely attributable to differences in animal types and individual responses [<xref rid="B41-vaccines-12-01304" ref-type="bibr">41</xref>]. Using aTJ and La Sota as four-unit antigens to measure pigeon HI antibody levels revealed a difference of up to 4 log2, indicating significant antigenic variations between the two strains [<xref rid="B30-vaccines-12-01304" ref-type="bibr">30</xref>]. HI titers against homologous antigens were significantly higher in different vaccine groups compared to heterologous antigens. Although La Sota is often used in HI tests for immunized animals, its titers may not fully correlate with protection against specific pathogens. To ensure accurate correlations between HI titers and protective efficacy, the challenge isolate should be used as the working antigen.</p><p>The virulent TJ-WT strain was used to challenge the pigeons on the 31 dpi. In the PBS control group, all pigeons exhibited symptoms from 4 dpc, with 100% incidence and mortality. In contrast, only one pigeon in the aTJ group showed mild symptoms, such as drooping wings, but did not worsen, and no deaths occurred. The incidence rate in the aTJ group was 10%, with a mortality rate of 0%. Antigen-matched vaccines have shown effective protection against viral challenges [<xref rid="B19-vaccines-12-01304" ref-type="bibr">19</xref>,<xref rid="B20-vaccines-12-01304" ref-type="bibr">20</xref>,<xref rid="B21-vaccines-12-01304" ref-type="bibr">21</xref>]. Vaccination strategies are effective in reducing the severity of clinical manifestations and mortality in poultry infected with NDV, though they do not entirely prevent infection or subsequent viral shedding. NDV primarily spreads through the fecal&#x02013;oral route [<xref rid="B42-vaccines-12-01304" ref-type="bibr">42</xref>], making the reduction of viral shedding vital for controlling transmission among poultry populations [<xref rid="B48-vaccines-12-01304" ref-type="bibr">48</xref>]. As a result, viral shedding is a key indicator of a vaccine&#x02019;s efficacy. The viral shedding rate in the PBS group was 100% on both the 5 and 10 dpc. In contrast, only three pigeons in the aTJ group with HI titers below 1 log2 were shedding the virus on 5 dpc, and only one symptomatic pigeon continued shedding on 10 dpc. This outcome underscores the aTJ vaccine&#x02019;s superior protective efficacy, showing a strong correlation between higher HI titers and enhanced immunological protection [<xref rid="B11-vaccines-12-01304" ref-type="bibr">11</xref>,<xref rid="B49-vaccines-12-01304" ref-type="bibr">49</xref>,<xref rid="B50-vaccines-12-01304" ref-type="bibr">50</xref>]. Although the aTJ vaccine demonstrated significant short-term efficacy in this study, the duration of vaccine-induced immunity remains a critical factor for the long-term control of PPMV-1. Future studies will extend the observation period to evaluate the persistence of HI titers, reduction in virus shedding, and the overall durability of immune protection over time. Such studies will provide a more comprehensive understanding of the vaccine&#x02019;s potential for sustained immunity and its practical application in pigeon breeding programs.</p></sec><sec sec-type="conclusions" id="sec5-vaccines-12-01304"><title>5. Conclusions</title><p>This study demonstrated the strong potential of the aTJ strain, developed through reverse genetic modification, as a live attenuated vaccine for PPMV-1 in pigeons. The vaccine effectively reduced virulence while maintaining immunogenicity, leading to a significant increase in HI titers after booster immunization, as well as reduced viral shedding and complete protection against mortality. These findings emphasize the importance of antigenic matching in vaccine design and provide a solid foundation for future research to evaluate the vaccine&#x02019;s long-term protective efficacy and practical applications in pigeon breeding programs.</p></sec></body><back><ack><title>Acknowledgments</title><p>We extend our sincere thanks to the team of Avian Viral Disease Surveillance, Early Warning and Prevention and Control of the Shanghai Veterinary Research Institute of Chinese Academy of Agricultural Sciences for their invaluable assistance and guidance in the PPMV-1 experiments.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-vaccines-12-01304"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at <uri xlink:href="https://www.mdpi.com/article/10.3390/vaccines12121304/s1">https://www.mdpi.com/article/10.3390/vaccines12121304/s1</uri>: Figure S1: PCR amplification of the TJ-WT genome segments; Figure S2: Construction of the full-length infectious clone. Figure S3: Clinical symptoms with corresponding scores. Table S1. Detailed clinical observations of pigeons in each group after the challenge.</p><supplementary-material id="vaccines-12-01304-s001" position="float" content-type="local-data"><media xlink:href="vaccines-12-01304-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, S.H. and X.Q.; methodology, X.Q. and S.Z.; software, S.Z.; validation, S.Z., D.L. and B.L.; formal analysis, S.Z.; investigation, X.T., L.L. and R.L.; resources, J.D., X.Q. and C.D.; data curation, S.Z.; writing&#x02014;original draft preparation, S.Z.; writing&#x02014;review and editing, X.T. and X.Q.; visualization, S.Z.; supervision, C.D. and J.D.; project administration, J.D. and X.Q.; funding acquisition, J.D. and X.Q. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The animal studies described in this work followed institutional guidelines for animal welfare and biosafety and were approved by the Animal Welfare and Ethics Committee of Institute of Animal Science, Chinese Academy of Agricultural Sciences (ISA2023-120).</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data presented in this study are available on request from the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>Baojing Liu is employed by Beijing Xinhexiang Technology Co., Ltd. The other authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-12-01304"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mayo</surname><given-names>M.A.</given-names></name>
</person-group><article-title>A summary of taxonomic changes recently approved by ICTV</article-title><source>Arch. Virol.</source><year>2002</year><volume>147</volume><fpage>1655</fpage><lpage>1663</lpage><pub-id pub-id-type="doi">10.1007/s007050200039</pub-id><pub-id pub-id-type="pmid">12181683</pub-id>
</element-citation></ref><ref id="B2-vaccines-12-01304"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dimitrov</surname><given-names>K.M.</given-names></name>
<name><surname>Abolnik</surname><given-names>C.</given-names></name>
<name><surname>Afonso</surname><given-names>C.L.</given-names></name>
<name><surname>Albina</surname><given-names>E.</given-names></name>
<name><surname>Bahl</surname><given-names>J.</given-names></name>
<name><surname>Berg</surname><given-names>M.</given-names></name>
<name><surname>Briand</surname><given-names>F.X.</given-names></name>
<name><surname>Brown</surname><given-names>I.H.</given-names></name>
<name><surname>Choi</surname><given-names>K.S.</given-names></name>
<name><surname>Chvala</surname><given-names>I.</given-names></name>
<etal/>
</person-group><article-title>Updated unified phylogenetic classification system and revised nomenclature for Newcastle disease virus</article-title><source>Infect. Genet. Evol.</source><year>2019</year><volume>74</volume><fpage>103917</fpage><pub-id pub-id-type="doi">10.1016/j.meegid.2019.103917</pub-id><pub-id pub-id-type="pmid">31200111</pub-id>
</element-citation></ref><ref id="B3-vaccines-12-01304"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Millar</surname><given-names>N.S.</given-names></name>
<name><surname>Chambers</surname><given-names>P.</given-names></name>
<name><surname>Emmerson</surname><given-names>P.T.</given-names></name>
</person-group><article-title>Nucleotide sequence of the fusion and haemagglutinin-neuraminidase glycoprotein genes of Newcastle disease virus, strain Ulster: Molecular basis for variations in pathogenicity between strains</article-title><source>J. Gen. Virol.</source><year>1988</year><volume>69</volume><issue-part>Pt 3</issue-part><fpage>613</fpage><lpage>620</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-69-3-613</pub-id><pub-id pub-id-type="pmid">3351479</pub-id>
</element-citation></ref><ref id="B4-vaccines-12-01304"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aldous</surname><given-names>E.W.</given-names></name>
<name><surname>Fuller</surname><given-names>C.M.</given-names></name>
<name><surname>Mynn</surname><given-names>J.K.</given-names></name>
<name><surname>Alexander</surname><given-names>D.J.</given-names></name>
</person-group><article-title>A molecular epidemiological investigation of isolates of the variant avian paramyxovirus type 1 virus (PPMV-1) responsible for the 1978 to present panzootic in pigeons</article-title><source>Avian Pathol</source><year>2004</year><volume>33</volume><fpage>258</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1080/0307945042000195768</pub-id><pub-id pub-id-type="pmid">15276997</pub-id>
</element-citation></ref><ref id="B5-vaccines-12-01304"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaleta</surname><given-names>E.F.</given-names></name>
<name><surname>Alexander</surname><given-names>D.J.</given-names></name>
<name><surname>Russell</surname><given-names>P.H.</given-names></name>
</person-group><article-title>The first isolation of the avian PMV-1 virus responsible for the current panzootic in pigeons ?</article-title><source>Avian Pathol.</source><year>1985</year><volume>14</volume><fpage>553</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1080/03079458508436258</pub-id><pub-id pub-id-type="pmid">18766949</pub-id>
</element-citation></ref><ref id="B6-vaccines-12-01304"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xie</surname><given-names>P.</given-names></name>
<name><surname>Chen</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Lin</surname><given-names>Q.</given-names></name>
<name><surname>Ding</surname><given-names>C.</given-names></name>
<name><surname>Liao</surname><given-names>M.</given-names></name>
<name><surname>Xu</surname><given-names>C.</given-names></name>
<name><surname>Xiang</surname><given-names>B.</given-names></name>
<name><surname>Ren</surname><given-names>T.</given-names></name>
</person-group><article-title>Evolutionary Dynamics and Age-Dependent Pathogenesis of Sub-Genotype VI.2.1.1.2.2 PPMV-1 in Pigeons</article-title><source>Viruses</source><year>2020</year><volume>12</volume><elocation-id>433</elocation-id><pub-id pub-id-type="doi">10.3390/v12040433</pub-id><pub-id pub-id-type="pmid">32290416</pub-id>
</element-citation></ref><ref id="B7-vaccines-12-01304"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ren</surname><given-names>S.</given-names></name>
<name><surname>Wang</surname><given-names>C.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Zhao</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Yao</surname><given-names>W.</given-names></name>
<name><surname>Han</surname><given-names>Q.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Fan</surname><given-names>M.</given-names></name>
<name><surname>Gao</surname><given-names>X.</given-names></name>
<etal/>
</person-group><article-title>Phylogenetic and pathogenic characterization of a pigeon paramyxovirus type 1 isolate reveals cross-species transmission and potential outbreak risks in the northwest region of China</article-title><source>Arch. Virol.</source><year>2017</year><volume>162</volume><fpage>2755</fpage><lpage>2767</lpage><pub-id pub-id-type="doi">10.1007/s00705-017-3422-1</pub-id><pub-id pub-id-type="pmid">28597087</pub-id>
</element-citation></ref><ref id="B8-vaccines-12-01304"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>&#x0015a;mietanka</surname><given-names>K.</given-names></name>
<name><surname>Olszewska</surname><given-names>M.</given-names></name>
<name><surname>Doma&#x00144;ska-Blicharz</surname><given-names>K.</given-names></name>
<name><surname>Bocian</surname><given-names>A.L.</given-names></name>
<name><surname>Minta</surname><given-names>Z.</given-names></name>
</person-group><article-title>Experimental infection of different species of birds with pigeon paramyxovirus type 1 virus&#x02014;Evaluation of clinical outcomes, viral shedding, and distribution in tissues</article-title><source>Avian Dis.</source><year>2014</year><volume>58</volume><fpage>523</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1637/10769-011514-Reg.1</pub-id><pub-id pub-id-type="pmid">25618996</pub-id>
</element-citation></ref><ref id="B9-vaccines-12-01304"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guo</surname><given-names>H.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Han</surname><given-names>Z.</given-names></name>
<name><surname>Shao</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Zhao</surname><given-names>S.</given-names></name>
<name><surname>Kong</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>S.</given-names></name>
</person-group><article-title>Phylogenetic analysis and comparison of eight strains of pigeon paramyxovirus type 1 (PPMV-1) isolated in China between 2010 and 2012</article-title><source>Arch. Virol.</source><year>2013</year><volume>158</volume><fpage>1121</fpage><lpage>1131</lpage><pub-id pub-id-type="doi">10.1007/s00705-012-1572-8</pub-id><pub-id pub-id-type="pmid">23292066</pub-id>
</element-citation></ref><ref id="B10-vaccines-12-01304"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>He</surname><given-names>Y.</given-names></name>
<name><surname>Lu</surname><given-names>B.</given-names></name>
<name><surname>Dimitrov</surname><given-names>K.M.</given-names></name>
<name><surname>Liang</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>Z.</given-names></name>
<name><surname>Zhao</surname><given-names>W.</given-names></name>
<name><surname>Qin</surname><given-names>Y.</given-names></name>
<name><surname>Duan</surname><given-names>Q.</given-names></name>
<name><surname>Zhou</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Complete Genome Sequencing, Molecular Epidemiological, and Pathogenicity Analysis of Pigeon Paramyxoviruses Type 1 Isolated in Guangxi, China during 2012&#x02013;2018</article-title><source>Viruses</source><year>2020</year><volume>12</volume><elocation-id>366</elocation-id><pub-id pub-id-type="doi">10.3390/v12040366</pub-id><pub-id pub-id-type="pmid">32224965</pub-id>
</element-citation></ref><ref id="B11-vaccines-12-01304"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dortmans</surname><given-names>J.C.</given-names></name>
<name><surname>Venema-Kemper</surname><given-names>S.</given-names></name>
<name><surname>Peeters</surname><given-names>B.P.</given-names></name>
<name><surname>Koch</surname><given-names>G.</given-names></name>
</person-group><article-title>Field vaccinated chickens with low antibody titres show equally insufficient protection against matching and non-matching genotypes of virulent Newcastle disease virus</article-title><source>Vet. Microbiol.</source><year>2014</year><volume>172</volume><fpage>100</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2014.05.004</pub-id><pub-id pub-id-type="pmid">24894134</pub-id>
</element-citation></ref><ref id="B12-vaccines-12-01304"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zeng</surname><given-names>T.</given-names></name>
<name><surname>Xie</surname><given-names>L.</given-names></name>
<name><surname>Xie</surname><given-names>Z.</given-names></name>
<name><surname>Hua</surname><given-names>J.</given-names></name>
<name><surname>Huang</surname><given-names>J.</given-names></name>
<name><surname>Xie</surname><given-names>Z.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>M.</given-names></name>
<name><surname>Luo</surname><given-names>S.</given-names></name>
<name><surname>Li</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Analysis of Newcastle disease virus prevalence in wild birds reveals interhost transmission of genotype VI strains</article-title><source>Microbiol. Spectr.</source><year>2024</year><elocation-id>e0081624</elocation-id><comment>Epub ahead of print</comment><pub-id pub-id-type="doi">10.1128/spectrum.00816-24</pub-id><pub-id pub-id-type="pmid">39513736</pub-id>
</element-citation></ref><ref id="B13-vaccines-12-01304"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>W.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>W.</given-names></name>
<name><surname>Bai</surname><given-names>J.</given-names></name>
<name><surname>Yang</surname><given-names>Z.</given-names></name>
<name><surname>Liu</surname><given-names>H.</given-names></name>
<name><surname>Xiao</surname><given-names>S.</given-names></name>
</person-group><article-title>A pigeon paramyxovirus type 1 isolated from racing pigeon as an inactivated vaccine candidate provides effective protection</article-title><source>Poult. Sci.</source><year>2022</year><volume>101</volume><fpage>102097</fpage><pub-id pub-id-type="doi">10.1016/j.psj.2022.102097</pub-id><pub-id pub-id-type="pmid">36055029</pub-id>
</element-citation></ref><ref id="B14-vaccines-12-01304"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abolnik</surname><given-names>C.</given-names></name>
</person-group><article-title>A current review of avian influenza in pigeons and doves (Columbidae)</article-title><source>Vet. Microbiol.</source><year>2014</year><volume>170</volume><fpage>181</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2014.02.042</pub-id><pub-id pub-id-type="pmid">24667061</pub-id>
</element-citation></ref><ref id="B15-vaccines-12-01304"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>M.</given-names></name>
<name><surname>Qu</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>F.</given-names></name>
<name><surname>Liu</surname><given-names>S.</given-names></name>
<name><surname>Sun</surname><given-names>H.</given-names></name>
</person-group><article-title>Genotypic and pathotypic characterization of Newcastle disease virus isolated from racing pigeons in China</article-title><source>Poult. Sci.</source><year>2015</year><volume>94</volume><fpage>1476</fpage><lpage>1482</lpage><pub-id pub-id-type="doi">10.3382/ps/pev106</pub-id><pub-id pub-id-type="pmid">25877412</pub-id>
</element-citation></ref><ref id="B16-vaccines-12-01304"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dortmans</surname><given-names>J.C.</given-names></name>
<name><surname>Rottier</surname><given-names>P.J.</given-names></name>
<name><surname>Koch</surname><given-names>G.</given-names></name>
<name><surname>Peeters</surname><given-names>B.P.</given-names></name>
</person-group><article-title>Passaging of a Newcastle disease virus pigeon variant in chickens results in selection of viruses with mutations in the polymerase complex enhancing virus replication and virulence</article-title><source>J. Gen. Virol.</source><year>2011</year><volume>92</volume><fpage>336</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1099/vir.0.026344-0</pub-id><pub-id pub-id-type="pmid">20965986</pub-id>
</element-citation></ref><ref id="B17-vaccines-12-01304"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kommers</surname><given-names>G.D.</given-names></name>
<name><surname>King</surname><given-names>D.J.</given-names></name>
<name><surname>Seal</surname><given-names>B.S.</given-names></name>
<name><surname>Brown</surname><given-names>C.C.</given-names></name>
</person-group><article-title>Virulence of six heterogeneous-origin Newcastle disease virus isolates before and after sequential passages in domestic chickens</article-title><source>Avian Pathol.</source><year>2003</year><volume>32</volume><fpage>81</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1080/0307945021000070750</pub-id><pub-id pub-id-type="pmid">12745384</pub-id>
</element-citation></ref><ref id="B18-vaccines-12-01304"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cui</surname><given-names>S.</given-names></name>
<name><surname>Xiong</surname><given-names>H.</given-names></name>
<name><surname>Feng</surname><given-names>Z.</given-names></name>
<name><surname>Chu</surname><given-names>Y.</given-names></name>
<name><surname>Que</surname><given-names>C.</given-names></name>
<name><surname>Qin</surname><given-names>J.</given-names></name>
<name><surname>Pan</surname><given-names>Y.</given-names></name>
<name><surname>Yu</surname><given-names>K.</given-names></name>
<name><surname>Jia</surname><given-names>L.</given-names></name>
<name><surname>Yao</surname><given-names>X.</given-names></name>
<etal/>
</person-group><article-title>Severe pigeon paramyxovirus 1 infection in a human case with probable post-COVID-19 condition</article-title><source>Emerg. Microbes Infect.</source><year>2023</year><volume>12</volume><fpage>2251600</fpage><pub-id pub-id-type="doi">10.1080/22221751.2023.2251600</pub-id><pub-id pub-id-type="pmid">37606967</pub-id>
</element-citation></ref><ref id="B19-vaccines-12-01304"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Miller</surname><given-names>P.J.</given-names></name>
<name><surname>King</surname><given-names>D.J.</given-names></name>
<name><surname>Afonso</surname><given-names>C.L.</given-names></name>
<name><surname>Suarez</surname><given-names>D.L.</given-names></name>
</person-group><article-title>Antigenic differences among Newcastle disease virus strains of different genotypes used in vaccine formulation affect viral shedding after a virulent challenge</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>7238</fpage><lpage>7246</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.07.017</pub-id><pub-id pub-id-type="pmid">17719150</pub-id>
</element-citation></ref><ref id="B20-vaccines-12-01304"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hu</surname><given-names>S.</given-names></name>
<name><surname>Ma</surname><given-names>H.</given-names></name>
<name><surname>Wu</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>W.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
</person-group><article-title>A vaccine candidate of attenuated genotype VII Newcastle disease virus generated by reverse genetics</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><fpage>904</fpage><lpage>910</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2008.11.091</pub-id><pub-id pub-id-type="pmid">19095026</pub-id>
</element-citation></ref><ref id="B21-vaccines-12-01304"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dimitrov</surname><given-names>K.M.</given-names></name>
<name><surname>Afonso</surname><given-names>C.L.</given-names></name>
<name><surname>Yu</surname><given-names>Q.</given-names></name>
<name><surname>Miller</surname><given-names>P.J.</given-names></name>
</person-group><article-title>Newcastle disease vaccines-A solved problem or a continuous challenge?</article-title><source>Vet. Microbiol.</source><year>2017</year><volume>206</volume><fpage>126</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2016.12.019</pub-id><pub-id pub-id-type="pmid">28024856</pub-id>
</element-citation></ref><ref id="B22-vaccines-12-01304"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hamouda</surname><given-names>E.E.</given-names></name>
<name><surname>Eid</surname><given-names>A.A.M.</given-names></name>
<name><surname>Gouda</surname><given-names>H.F.</given-names></name>
<name><surname>Dessouki</surname><given-names>A.A.</given-names></name>
<name><surname>El-Deeb</surname><given-names>A.H.</given-names></name>
<name><surname>Daines</surname><given-names>R.</given-names></name>
<name><surname>Iqbal</surname><given-names>M.</given-names></name>
<name><surname>ElBakrey</surname><given-names>R.M.</given-names></name>
</person-group><article-title>Assessment of PPMV-1 Genotype VI Virulence in Pigeons and Chickens and Protective Effectiveness of Paramyxovirus Vaccines in Pigeons</article-title><source>Viruses</source><year>2024</year><volume>16</volume><elocation-id>1585</elocation-id><pub-id pub-id-type="doi">10.3390/v16101585</pub-id><pub-id pub-id-type="pmid">39459921</pub-id>
</element-citation></ref><ref id="B23-vaccines-12-01304"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dimitrov</surname><given-names>K.M.</given-names></name>
<name><surname>Ramey</surname><given-names>A.M.</given-names></name>
<name><surname>Qiu</surname><given-names>X.</given-names></name>
<name><surname>Bahl</surname><given-names>J.</given-names></name>
<name><surname>Afonso</surname><given-names>C.L.</given-names></name>
</person-group><article-title>Temporal, geographic, and host distribution of avian paramyxovirus 1 (Newcastle disease virus)</article-title><source>Infect. Genet. Evol.</source><year>2016</year><volume>39</volume><fpage>22</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.meegid.2016.01.008</pub-id><pub-id pub-id-type="pmid">26792710</pub-id>
</element-citation></ref><ref id="B24-vaccines-12-01304"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wakamatsu</surname><given-names>N.</given-names></name>
<name><surname>King</surname><given-names>D.J.</given-names></name>
<name><surname>Seal</surname><given-names>B.S.</given-names></name>
<name><surname>Peeters</surname><given-names>B.P.</given-names></name>
<name><surname>Brown</surname><given-names>C.C.</given-names></name>
</person-group><article-title>The effect on pathogenesis of Newcastle disease virus LaSota strain from a mutation of the fusion cleavage site to a virulent sequence</article-title><source>Avian Dis.</source><year>2006</year><volume>50</volume><fpage>483</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.1637/7515-020706R.1</pub-id><pub-id pub-id-type="pmid">17274282</pub-id>
</element-citation></ref><ref id="B25-vaccines-12-01304"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ganar</surname><given-names>K.</given-names></name>
<name><surname>Das</surname><given-names>M.</given-names></name>
<name><surname>Sinha</surname><given-names>S.</given-names></name>
<name><surname>Kumar</surname><given-names>S.</given-names></name>
</person-group><article-title>Newcastle disease virus: Current status and our understanding</article-title><source>Virus Res.</source><year>2014</year><volume>184</volume><fpage>71</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2014.02.016</pub-id><pub-id pub-id-type="pmid">24589707</pub-id>
</element-citation></ref><ref id="B26-vaccines-12-01304"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dortmans</surname><given-names>J.C.</given-names></name>
<name><surname>Koch</surname><given-names>G.</given-names></name>
<name><surname>Rottier</surname><given-names>P.J.</given-names></name>
<name><surname>Peeters</surname><given-names>B.P.</given-names></name>
</person-group><article-title>Virulence of Newcastle disease virus: What is known so far?</article-title><source>Vet. Res.</source><year>2011</year><volume>42</volume><fpage>122</fpage><pub-id pub-id-type="doi">10.1186/1297-9716-42-122</pub-id><pub-id pub-id-type="pmid">22195547</pub-id>
</element-citation></ref><ref id="B27-vaccines-12-01304"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Selim</surname><given-names>K.M.</given-names></name>
<name><surname>Selim</surname><given-names>A.</given-names></name>
<name><surname>Arafa</surname><given-names>A.</given-names></name>
<name><surname>Hussein</surname><given-names>H.A.</given-names></name>
<name><surname>Elsanousi</surname><given-names>A.A.</given-names></name>
</person-group><article-title>Molecular characterization of full fusion protein (F) of Newcastle disease virus genotype VIId isolated from Egypt during 2012&#x02013;2016</article-title><source>Vet World</source><year>2018</year><volume>11</volume><fpage>930</fpage><lpage>938</lpage><pub-id pub-id-type="doi">10.14202/vetworld.2018.930-938</pub-id><pub-id pub-id-type="pmid">30147262</pub-id>
</element-citation></ref><ref id="B28-vaccines-12-01304"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peeters</surname><given-names>B.P.</given-names></name>
<name><surname>de Leeuw</surname><given-names>O.S.</given-names></name>
<name><surname>Koch</surname><given-names>G.</given-names></name>
<name><surname>Gielkens</surname><given-names>A.L.</given-names></name>
</person-group><article-title>Rescue of Newcastle disease virus from cloned cDNA: Evidence that cleavability of the fusion protein is a major determinant for virulence</article-title><source>J. Virol.</source><year>1999</year><volume>73</volume><fpage>5001</fpage><lpage>5009</lpage><pub-id pub-id-type="doi">10.1128/JVI.73.6.5001-5009.1999</pub-id><pub-id pub-id-type="pmid">10233962</pub-id>
</element-citation></ref><ref id="B29-vaccines-12-01304"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xiao</surname><given-names>S.</given-names></name>
<name><surname>Nayak</surname><given-names>B.</given-names></name>
<name><surname>Samuel</surname><given-names>A.</given-names></name>
<name><surname>Paldurai</surname><given-names>A.</given-names></name>
<name><surname>Kanabagattebasavarajappa</surname><given-names>M.</given-names></name>
<name><surname>Prajitno</surname><given-names>T.Y.</given-names></name>
<name><surname>Bharoto</surname><given-names>E.E.</given-names></name>
<name><surname>Collins</surname><given-names>P.L.</given-names></name>
<name><surname>Samal</surname><given-names>S.K.</given-names></name>
</person-group><article-title>Generation by reverse genetics of an effective, stable, live-attenuated newcastle disease virus vaccine based on a currently circulating, highly virulent Indonesian strain</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e52751</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0052751</pub-id><pub-id pub-id-type="pmid">23285174</pub-id>
</element-citation></ref><ref id="B30-vaccines-12-01304"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>S.</given-names></name>
<name><surname>Liu</surname><given-names>D.</given-names></name>
<name><surname>Liu</surname><given-names>B.</given-names></name>
<name><surname>Liang</surname><given-names>L.</given-names></name>
<name><surname>Liang</surname><given-names>R.</given-names></name>
<name><surname>Tang</surname><given-names>X.</given-names></name>
<name><surname>Qiu</surname><given-names>X.</given-names></name>
<name><surname>Ding</surname><given-names>C.</given-names></name>
<name><surname>Ding</surname><given-names>J.</given-names></name>
<name><surname>Hou</surname><given-names>S.</given-names></name>
</person-group><article-title>Isolation, identification and pathogenicity analysis of pigeon paramyxovirus-1 TJ20 strain</article-title><source>Acta Vet. Zootech. Sin.</source><year>2024</year><volume>55</volume><fpage>4051</fpage><lpage>4060</lpage></element-citation></ref><ref id="B31-vaccines-12-01304"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peng</surname><given-names>T.</given-names></name>
<name><surname>Qiu</surname><given-names>X.</given-names></name>
<name><surname>Tan</surname><given-names>L.</given-names></name>
<name><surname>Yu</surname><given-names>S.</given-names></name>
<name><surname>Yang</surname><given-names>B.</given-names></name>
<name><surname>Dai</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Sun</surname><given-names>Y.</given-names></name>
<name><surname>Song</surname><given-names>C.</given-names></name>
<name><surname>Liu</surname><given-names>W.</given-names></name>
<etal/>
</person-group><article-title>Ubiquitination on Lysine 247 of Newcastle Disease Virus Matrix Protein Enhances Viral Replication and Virulence by Driving Nuclear-Cytoplasmic Trafficking</article-title><source>J. Virol.</source><year>2022</year><volume>96</volume><fpage>e0162921</fpage><pub-id pub-id-type="doi">10.1128/JVI.01629-21</pub-id><pub-id pub-id-type="pmid">34705566</pub-id>
</element-citation></ref><ref id="B32-vaccines-12-01304"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhan</surname><given-names>T.</given-names></name>
<name><surname>He</surname><given-names>D.</given-names></name>
<name><surname>Lu</surname><given-names>X.</given-names></name>
<name><surname>Liao</surname><given-names>T.</given-names></name>
<name><surname>Wang</surname><given-names>W.</given-names></name>
<name><surname>Chen</surname><given-names>Q.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Gu</surname><given-names>M.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Hu</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Biological Characterization and Evolutionary Dynamics of Pigeon Paramyxovirus Type 1 in China</article-title><source>Front. Vet. Sci.</source><year>2021</year><volume>8</volume><elocation-id>721102</elocation-id><pub-id pub-id-type="doi">10.3389/fvets.2021.721102</pub-id><pub-id pub-id-type="pmid">34722696</pub-id>
</element-citation></ref><ref id="B33-vaccines-12-01304"><label>33.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>WOAH</collab>
</person-group><article-title>Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, World Organisation for Animal Health, Twelfth Edition 2023 Chapter 3.3.14</article-title><comment>Available online: <ext-link xlink:href="https://www.woah.org/fileadmin/Home/eng/Health_standards/tahm/3.03.14_NEWCASTLE_DIS.pdf" ext-link-type="uri">https://www.woah.org/fileadmin/Home/eng/Health_standards/tahm/3.03.14_NEWCASTLE_DIS.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-10-09">(accessed on 9 October 2024)</date-in-citation></element-citation></ref><ref id="B34-vaccines-12-01304"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lei</surname><given-names>C.</given-names></name>
<name><surname>Yang</surname><given-names>J.</given-names></name>
<name><surname>Hu</surname><given-names>J.</given-names></name>
<name><surname>Sun</surname><given-names>X.</given-names></name>
</person-group><article-title>On the Calculation of TCID(50) for Quantitation of Virus Infectivity</article-title><source>Virol. Sin.</source><year>2021</year><volume>36</volume><fpage>141</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1007/s12250-020-00230-5</pub-id><pub-id pub-id-type="pmid">32458296</pub-id>
</element-citation></ref><ref id="B35-vaccines-12-01304"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>X.</given-names></name>
<name><surname>Chen</surname><given-names>S.</given-names></name>
<name><surname>Chen</surname><given-names>H.</given-names></name>
<name><surname>Tian</surname><given-names>J.</given-names></name>
<name><surname>Zhao</surname><given-names>X.</given-names></name>
<name><surname>Jia</surname><given-names>Y.</given-names></name>
<name><surname>Xiao</surname><given-names>S.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>H.</given-names></name>
<name><surname>Yang</surname><given-names>Z.</given-names></name>
</person-group><article-title>Comparative biology of two genetically closely related Newcastle disease virus strains with strongly contrasting pathogenicity</article-title><source>Vet. Microbiol.</source><year>2021</year><volume>253</volume><elocation-id>108977</elocation-id><pub-id pub-id-type="doi">10.1016/j.vetmic.2020.108977</pub-id><pub-id pub-id-type="pmid">33421684</pub-id>
</element-citation></ref><ref id="B36-vaccines-12-01304"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Paldurai</surname><given-names>A.</given-names></name>
<name><surname>Kim</surname><given-names>S.H.</given-names></name>
<name><surname>Nayak</surname><given-names>B.</given-names></name>
<name><surname>Xiao</surname><given-names>S.</given-names></name>
<name><surname>Shive</surname><given-names>H.</given-names></name>
<name><surname>Collins</surname><given-names>P.L.</given-names></name>
<name><surname>Samal</surname><given-names>S.K.</given-names></name>
</person-group><article-title>Evaluation of the contributions of individual viral genes to newcastle disease virus virulence and pathogenesis</article-title><source>J. Virol.</source><year>2014</year><volume>88</volume><fpage>8579</fpage><lpage>8596</lpage><pub-id pub-id-type="doi">10.1128/JVI.00666-14</pub-id><pub-id pub-id-type="pmid">24850737</pub-id>
</element-citation></ref><ref id="B37-vaccines-12-01304"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tian</surname><given-names>Y.</given-names></name>
<name><surname>Xue</surname><given-names>R.</given-names></name>
<name><surname>Yang</surname><given-names>W.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Xue</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>G.</given-names></name>
</person-group><article-title>Characterization of ten paramyxovirus type 1 viruses isolated from pigeons in China during 1996-2019</article-title><source>Vet Microbiol.</source><year>2020</year><volume>244</volume><elocation-id>108661</elocation-id><pub-id pub-id-type="doi">10.1016/j.vetmic.2020.108661</pub-id><pub-id pub-id-type="pmid">32402346</pub-id>
</element-citation></ref><ref id="B38-vaccines-12-01304"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhan</surname><given-names>T.</given-names></name>
<name><surname>Lu</surname><given-names>X.</given-names></name>
<name><surname>He</surname><given-names>D.</given-names></name>
<name><surname>Gao</surname><given-names>X.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Hu</surname><given-names>Z.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Hu</surname><given-names>S.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
</person-group><article-title>Phylogenetic analysis and pathogenicity assessment of pigeon paramyxovirus type 1 circulating in China during 2007&#x02013;2019</article-title><source>Transbound. Emerg. Dis.</source><year>2022</year><volume>69</volume><fpage>2076</fpage><lpage>2088</lpage><pub-id pub-id-type="doi">10.1111/tbed.14215</pub-id><pub-id pub-id-type="pmid">34213072</pub-id>
</element-citation></ref><ref id="B39-vaccines-12-01304"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>H.M.</given-names></name>
<name><surname>Zhao</surname><given-names>J.</given-names></name>
<name><surname>Xue</surname><given-names>J.</given-names></name>
<name><surname>Yang</surname><given-names>Y.L.</given-names></name>
<name><surname>Zhang</surname><given-names>G.Z.</given-names></name>
</person-group><article-title>Antigenic variation of LaSota and genotype VII Newcastle disease virus (NDV) and their efficacy against challenge with velogenic NDV</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><fpage>27</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.11.048</pub-id><pub-id pub-id-type="pmid">27889255</pub-id>
</element-citation></ref><ref id="B40-vaccines-12-01304"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>M.M.</given-names></name>
<name><surname>Cheng</surname><given-names>J.L.</given-names></name>
<name><surname>Yu</surname><given-names>X.H.</given-names></name>
<name><surname>Qin</surname><given-names>Z.M.</given-names></name>
<name><surname>Tian</surname><given-names>F.L.</given-names></name>
<name><surname>Zhang</surname><given-names>G.Z.</given-names></name>
</person-group><article-title>Generation by reverse genetics of an effective attenuated Newcastle disease virus vaccine based on a prevalent highly virulent Chinese strain</article-title><source>Biotechnol. Lett.</source><year>2015</year><volume>37</volume><fpage>1287</fpage><lpage>1296</lpage><pub-id pub-id-type="doi">10.1007/s10529-015-1799-z</pub-id><pub-id pub-id-type="pmid">25724719</pub-id>
</element-citation></ref><ref id="B41-vaccines-12-01304"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guo</surname><given-names>H.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Xu</surname><given-names>Y.</given-names></name>
<name><surname>Han</surname><given-names>Z.</given-names></name>
<name><surname>Shao</surname><given-names>Y.</given-names></name>
<name><surname>Kong</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>S.</given-names></name>
</person-group><article-title>A comparative study of pigeons and chickens experimentally infected with PPMV-1 to determine antigenic relationships between PPMV-1 and NDV strains</article-title><source>Vet. Microbiol.</source><year>2014</year><volume>168</volume><fpage>88</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2013.11.002</pub-id><pub-id pub-id-type="pmid">24314393</pub-id>
</element-citation></ref><ref id="B42-vaccines-12-01304"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kapczynski</surname><given-names>D.R.</given-names></name>
<name><surname>Afonso</surname><given-names>C.L.</given-names></name>
<name><surname>Miller</surname><given-names>P.J.</given-names></name>
</person-group><article-title>Immune responses of poultry to Newcastle disease virus</article-title><source>Dev. Comp. Immunol.</source><year>2013</year><volume>41</volume><fpage>447</fpage><lpage>453</lpage><pub-id pub-id-type="doi">10.1016/j.dci.2013.04.012</pub-id><pub-id pub-id-type="pmid">23623955</pub-id>
</element-citation></ref><ref id="B43-vaccines-12-01304"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>W.Q.</given-names></name>
<name><surname>Tian</surname><given-names>M.X.</given-names></name>
<name><surname>Wang</surname><given-names>Y.P.</given-names></name>
<name><surname>Zhao</surname><given-names>Y.</given-names></name>
<name><surname>Zou</surname><given-names>N.L.</given-names></name>
<name><surname>Zhao</surname><given-names>F.F.</given-names></name>
<name><surname>Cao</surname><given-names>S.J.</given-names></name>
<name><surname>Wen</surname><given-names>X.T.</given-names></name>
<name><surname>Liu</surname><given-names>P.</given-names></name>
<name><surname>Huang</surname><given-names>Y.</given-names></name>
</person-group><article-title>The different expression of immune-related cytokine genes in response to velogenic and lentogenic Newcastle disease viruses infection in chicken peripheral blood</article-title><source>Mol. Biol. Rep.</source><year>2012</year><volume>39</volume><fpage>3611</fpage><lpage>3618</lpage><pub-id pub-id-type="doi">10.1007/s11033-011-1135-1</pub-id><pub-id pub-id-type="pmid">21728003</pub-id>
</element-citation></ref><ref id="B44-vaccines-12-01304"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ahmed</surname><given-names>K.A.</given-names></name>
<name><surname>Saxena</surname><given-names>V.K.</given-names></name>
<name><surname>Ara</surname><given-names>A.</given-names></name>
<name><surname>Singh</surname><given-names>K.B.</given-names></name>
<name><surname>Sundaresan</surname><given-names>N.R.</given-names></name>
<name><surname>Saxena</surname><given-names>M.</given-names></name>
<name><surname>Rasool</surname><given-names>T.J.</given-names></name>
</person-group><article-title>Immune response to Newcastle disease virus in chicken lines divergently selected for cutaneous hypersensitivity</article-title><source>Int. J. Immunogenet.</source><year>2007</year><volume>34</volume><fpage>445</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1111/j.1744-313X.2007.00722.x</pub-id><pub-id pub-id-type="pmid">18001302</pub-id>
</element-citation></ref><ref id="B45-vaccines-12-01304"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Degen</surname><given-names>W.G.</given-names></name>
<name><surname>Daal</surname><given-names>N.</given-names></name>
<name><surname>Rothwell</surname><given-names>L.</given-names></name>
<name><surname>Kaiser</surname><given-names>P.</given-names></name>
<name><surname>Schijns</surname><given-names>V.E.</given-names></name>
</person-group><article-title>Th1/Th2 polarization by viral and helminth infection in birds</article-title><source>Vet. Microbiol.</source><year>2005</year><volume>105</volume><fpage>163</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2004.12.001</pub-id><pub-id pub-id-type="pmid">15708812</pub-id>
</element-citation></ref><ref id="B46-vaccines-12-01304"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>H.</given-names></name>
<name><surname>Tian</surname><given-names>J.</given-names></name>
<name><surname>Lu</surname><given-names>K.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Guan</surname><given-names>Z.</given-names></name>
<name><surname>Cao</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Chang</surname><given-names>Z.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Sa</surname><given-names>X.</given-names></name>
<etal/>
</person-group><article-title>Chicken ISG12(2) attenuates Newcastle disease virus and enhances the efficiency of Newcastle disease vaccine via activating immune pathways</article-title><source>Transbound. Emerg. Dis.</source><year>2022</year><volume>69</volume><fpage>2634</fpage><lpage>2648</lpage><pub-id pub-id-type="doi">10.1111/tbed.14416</pub-id><pub-id pub-id-type="pmid">34904395</pub-id>
</element-citation></ref><ref id="B47-vaccines-12-01304"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>D.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Xu</surname><given-names>L.</given-names></name>
<name><surname>Hu</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>B.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
</person-group><article-title>Immunologic synergism with IL-2 and effects of cCHMIs on mRNA expression of IL-2 and IFN-gamma in chicken peripheral T lymphocyte</article-title><source>Vaccine</source><year>2006</year><volume>24</volume><fpage>7109</fpage><lpage>7114</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.07.005</pub-id><pub-id pub-id-type="pmid">16887240</pub-id>
</element-citation></ref><ref id="B48-vaccines-12-01304"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cornelissen</surname><given-names>L.A.</given-names></name>
<name><surname>de Leeuw</surname><given-names>O.S.</given-names></name>
<name><surname>Tacken</surname><given-names>M.G.</given-names></name>
<name><surname>Klos</surname><given-names>H.C.</given-names></name>
<name><surname>de Vries</surname><given-names>R.P.</given-names></name>
<name><surname>de Boer-Luijtze</surname><given-names>E.A.</given-names></name>
<name><surname>van Zoelen-Bos</surname><given-names>D.J.</given-names></name>
<name><surname>Rigter</surname><given-names>A.</given-names></name>
<name><surname>Rottier</surname><given-names>P.J.</given-names></name>
<name><surname>Moormann</surname><given-names>R.J.</given-names></name>
<etal/>
</person-group><article-title>Protective efficacy of Newcastle disease virus expressing soluble trimeric hemagglutinin against highly pathogenic H5N1 influenza in chickens and mice</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e44447</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0044447</pub-id><pub-id pub-id-type="pmid">22952980</pub-id>
</element-citation></ref><ref id="B49-vaccines-12-01304"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Miller</surname><given-names>P.J.</given-names></name>
<name><surname>Afonso</surname><given-names>C.L.</given-names></name>
<name><surname>El Attrache</surname><given-names>J.</given-names></name>
<name><surname>Dorsey</surname><given-names>K.M.</given-names></name>
<name><surname>Courtney</surname><given-names>S.C.</given-names></name>
<name><surname>Guo</surname><given-names>Z.</given-names></name>
<name><surname>Kapczynski</surname><given-names>D.R.</given-names></name>
</person-group><article-title>Effects of Newcastle disease virus vaccine antibodies on the shedding and transmission of challenge viruses</article-title><source>Dev. Comp. Immunol.</source><year>2013</year><volume>41</volume><fpage>505</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1016/j.dci.2013.06.007</pub-id><pub-id pub-id-type="pmid">23796788</pub-id>
</element-citation></ref><ref id="B50-vaccines-12-01304"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dortmans</surname><given-names>J.C.</given-names></name>
<name><surname>Peeters</surname><given-names>B.P.</given-names></name>
<name><surname>Koch</surname><given-names>G.</given-names></name>
</person-group><article-title>Newcastle disease virus outbreaks: Vaccine mismatch or inadequate application?</article-title><source>Vet. Microbiol.</source><year>2012</year><volume>160</volume><fpage>17</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2012.05.003</pub-id><pub-id pub-id-type="pmid">22655976</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="vaccines-12-01304-f001"><label>Figure 1</label><caption><p>Schematic representation of the construction of the full-length genome plasmid TVT-aTJ for reverse genetics of the TJ-WT strain. The TJ-WT genome was divided into five segments (C1, S2, S3, C4, and C5) for sequential ligation into the pTVT vector using homologous recombination. MluI restriction enzyme digestion was employed to facilitate the insertion of the S3, C4, and C5 fragments. The label &#x0201c;F0&#x0201d; indicates the cleavage site of the F protein (Fcs), which was replaced with that of the La Sota strain. This process resulted in the construction of the full-length infectious clone, TVT-aTJ.</p></caption><graphic xlink:href="vaccines-12-01304-g001" position="float"/></fig><fig position="float" id="vaccines-12-01304-f002"><label>Figure 2</label><caption><p>Detection of genetic marker and F protein cleavage site mutations in the recombinant aTJ virus. (<bold>A</bold>) Agarose gel electrophoresis of PCR products before digestion (BD) and after digestion (AD) with KpnI. Lane M represented the molecular marker. TJ-WT represented the wild-type strain, and aTJ represented the recombinant virus strain. The expected band pattern confirmed the successful digestion at the KpnI site in the recombinant virus. (<bold>B</bold>) Sequencing chromatogram showing the Fcs. TJ-WT exhibited the virulent cleavage site <sub>112</sub>RRQKRF<sub>117</sub>, whereas the recombinant aTJ strain had the attenuated cleavage site <sub>112</sub>GRQGRL<sub>117</sub>. Red arrows marked the nucleotide changes, and the corresponding amino acid substitutions (in red) represented the introduction of the avirulent cleavage site.</p></caption><graphic xlink:href="vaccines-12-01304-g002" position="float"/></fig><fig position="float" id="vaccines-12-01304-f003"><label>Figure 3</label><caption><p>Viral growth kinetics in BHK21 cells. Cells were infected with each virus at a multiplicity of infection (MOI) of 1. Supernatants were collected every 12 h, and viral titers were determined using TCID<sub>50</sub> assays. Data are expressed as the mean &#x000b1; standard deviation from three independent experiments.</p></caption><graphic xlink:href="vaccines-12-01304-g003" position="float"/></fig><fig position="float" id="vaccines-12-01304-f004"><label>Figure 4</label><caption><p>Hemagglutination inhibition (HI) titers post-immunization. Serum samples were collected at 7, 14, 21, 28, and 31 days post-primary immunization (dpi), and HI titers were measured using aTJ (<bold>A</bold>) and La Sota (<bold>B</bold>) as 4 HA unit antigens. Antibody titers are shown as log<sub>2</sub> values, and data are presented as the median and interquartile range (IQR) (<italic toggle="yes">n</italic> = 10/group). A booster immunization was given on 21 dpi. Statistical comparisons were made using the nonparametric Mann&#x02013;Whitney <italic toggle="yes">U</italic> test. Significance levels: ** <italic toggle="yes">p</italic> &#x0003c; 0.01 and *** <italic toggle="yes">p</italic> &#x0003c; 0.001. Values without asterisks indicate no statistically significant difference.</p></caption><graphic xlink:href="vaccines-12-01304-g004" position="float"/></fig><fig position="float" id="vaccines-12-01304-f005"><label>Figure 5</label><caption><p>Clinical scores and survival curves post-challenge with the TJ-WT strain. (<bold>A</bold>) Clinical scores for each group of inactivated vaccines. Clinical scores for each group were expressed as the mean &#x000b1; standard error of the mean (SEM). The clinical symptoms were assessed based on the scoring criteria: 0 points for normal state; 1 point for depression or neck shrinkage; 2 points for drooping wings, torticollis, or ataxia; 3 points for general paralysis or collapse; and 4 points for death. (<bold>B</bold>) Survival curves for the groups after the challenge. Mortality rates were 100% in the PBS group, while mortality in the aTJ groups was 0%.</p></caption><graphic xlink:href="vaccines-12-01304-g005" position="float"/></fig><table-wrap position="float" id="vaccines-12-01304-t001"><object-id pub-id-type="pii">vaccines-12-01304-t001_Table 1</object-id><label>Table 1</label><caption><p>Primers used for virus rescue and identification.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Primer Names</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Primer Sequence (5&#x02032;&#x02192;3&#x02032;)</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C1-F</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CGACTCACTATAGGACCAAACAGAGAATCCGTGAGTTA</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C1-R</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CC<italic toggle="yes">gGTaCC</italic>TTGTAGGACGATC</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S2-F</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GTTAGCATTCCCGATCGTCCTACAA<italic toggle="yes">GGtACc</italic>GGTG</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S2-R</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AGGAGGTGGAGATGCCATGCCGACCC<italic toggle="yes">ACGCGT</italic>TATaAGgCGCccCTGTCTCCc</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S3-F</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GAgGGAGaCAGggGCGCCTTATAG</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S3-R</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GTGGAGATGCCATGCCGACCC<italic toggle="yes">ACGCGT</italic>GGAGCTCGCCATTTCCTACCCG</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C4-F</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACGGGTAGGAAATGGCGAG</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C4-R</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AGGAGGTGGAGATGCCATGCCGACCC<italic toggle="yes">ACGCGT</italic>CTGTTCCGGGCATAGTCTG</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C5-F</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CTCGCTGACGCTAGCAG</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C5-R</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GAGGAGGTGGAGATGCCATGCCGACCCACCAAACAAAGATTTGGTGAATG</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TVT-F</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GGGTCGGCATGGCATCTCCAC</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TVT-R</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TGGTCCTATAGTGAGTCGTATTAATTTCGCGGG</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6NP-F</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CACTATAGGCTAGCCTCGAG<underline>GCCACC</underline>ATGTCGTCCGTCTTTG</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6NP-R</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CTCTAGAGGTACCACGCGTTCAGTACCCCCAGTCGGTG</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6P-F</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CACTATAGGCTAGCCTCGAG<underline>GCCACC</underline>ATGGCAACTTTTACTGATGCTG</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6P-R</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TCTAGAGGTACCACGCGTTCAACCATTCAGTGCAAGGC</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6L1-F</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CACTATAGGCTAGCCTCGAG<underline>GCCACC</underline>ATGGCGAGCTCCGGTCCTGAAAG</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6L1-R</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GCTAGCGTCAGCGAGCACATAGC</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6L2-F</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GTCTGCTATGTGCTCGCTG</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6L2-R</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CTCTAGAGGTACCACGCGTTTAGGAGTCATTGTTACTGTAATATCCCTTTG</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">pCI-V-F</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACGCGTGGTACCTCTAGAGTC</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">pCI-V-R</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CTCGAGGCTAGCCTATAGTGAGTC</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PPMV1-3F <sup>1</sup></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TCAAAGCAGACATCCTCCA</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PPMV1-3R <sup>1</sup></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AAATGTMACTTTCTTTCCCCTCT</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PPMV1-4F <sup>2</sup></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ATGTCACTATTGAYGTGGAGGTA</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PPMV1-4R <sup>2</sup></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GGACAAGTGCTGAGGCAAAYC</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> Primers were used to detect genetic markers. <sup>2</sup> Primers were used to detect the Fcs. Lowercase letters represented mutated bases, italicized letters indicated restriction enzyme recognition sites, and underlined text denoted the Kozak sequence.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-12-01304-t003"><object-id pub-id-type="pii">vaccines-12-01304-t003_Table 3</object-id><label>Table 3</label><caption><p>Frequency of isolation of the challenge virus in different vaccine groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Groups</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Number</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Virus Shedding</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Morbidity</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Mortality</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 dpc</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 dpc</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">aTJ</td><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">3/10</td><td align="center" valign="middle" rowspan="1" colspan="1">1/10</td><td align="center" valign="middle" rowspan="1" colspan="1">1/10</td><td align="center" valign="middle" rowspan="1" colspan="1">0/10</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PBS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10/10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5/5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10/10 ***</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10/10 ****</td></tr></tbody></table><table-wrap-foot><fn><p>The number &#x0201c;n/m&#x0201d; indicates the number of positives detected and the total number of related samples. &#x0201c;dpc&#x0201d; represents days post-challenge. Statistical significance was analyzed using the chi-square (and Fisher&#x02019;s exact) test with GraphPad Prism software 9.5. *** <italic toggle="yes">p</italic> &#x0003c; 0.001, and **** <italic toggle="yes">p</italic> &#x0003c; 0.0001.</p></fn></table-wrap-foot></table-wrap></floats-group></article>